IB COMMUNICATIONS PRESS RELEASES

Lakewood, Colorado, U.S., September 23, 2024 - Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company , announced a collaboration with Nova Biomedical (Nova) to enable automated cell culture sensing with Terumo BCT’s Quantum Flex™ Cell Expansion System through integration with Nova’s BioProfile FLEX2 Automated Cell Culture Analyzer. By adding the FLEX2’s on-line automated sampling capabilities, it is possible to automatically sample and analyze a wide array of analytes in Quantum Flex and provide data in near-real time, unlocking more efficient process development and control.

St. Paul, MN – September 18, 2024 – ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReadyTM, today announced that ImmunoScape (a Singapore-U.S. based TCR-T therapy company) has been awarded a G-Rex® Grant.  ImmunoScape’s $250,000 G-Rex® Grant will enable process development and IND enabling studies of their novel WT1-targeted TCR-T cell therapy.

ST. PAUL, MN – September 17, 2024 – ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM, today announced that it has awarded a $150,000 G-Rex Grant to Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology.  This grant will support Verismo Therapeutics' ongoing efforts to optimize the development and manufacturing of its KIR-CAR platform using the G-Rex.

Miami, Florida, September 17, 2024 – OrganaBio, the cell and gene therapy industry’s hub for tissue sourcing, cell isolation, cryopreservation and clinical sample processing, today announced an expansion of its cell and gene therapy (CGT) starting materials donor base to include patients with over 200 diseases and conditions, including lupus and more than a dozen of the most common autoimmune diseases.

Stem cell charity Anthony Nolan has announced the opening of the Anthony Nolan Cell Collection Centre in Nottingham, UK.  
Founded in 1974, Anthony Nolan created the world’s first stem cell register and has since been a pivotal resource for medical teams seeking unrelated donor transplants for patients, as well as for researchers in the biotech and pharmaceutical industries.

Boca Raton, Florida, September 4, 2024 –  Kosten Digital, a leading developer of custom AI and digital solutions for the healthcare industry, has officially launched in the United States to drive the digital transformation of life sciences and healthcare companies.

Mulhouse, France, August 29, 2024 – CellProthera, a regenerative cell therapy developer specialising in ischemic diseases, announced alignment with regulators on a planned pivotal Phase III trial design for its ProtheraCytes® cell therapy following the completion of its pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA).

ST. PAUL, Minn., Aug. 27, 2024 - ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine's Laboratory for Cell and Gene Medicine (LCGM), has been awarded the inaugural G-Rex® Grant.

Ormond Beach, Fla. and Gaithersburg, Md., August 21, 2024 – GermFree, a pioneering leader in modular cleanroom infrastructure and services, and Caring Cross, a forward-thinking 501(c)(3) nonprofit committed to accelerating the development of advanced medicines and ensuring patient access to transformative therapies, today announced a new partnership to transform access to cell and gene therapies (CGTs).

Bristol, UK, 20 August 2024 – eXmoor pharma, the full-service cell and gene therapy (CGT) manufacturing partner, announced it has received a Manufacturing and Import Authorisation for Investigational Medicinal Products (MIA(IMP)) license from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), authorizing the manufacture of good manufacturing practice (GMP)-grade cell and gene therapy materials for use in clinical trials.

Lakewood, Colorado, August 15, 2024 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company , and Charles River Laboratories (Charles River), a global industry-leading drug discovery, preclinical development, manufacturing and testing solutions provider, announced data from a collaborative project demonstrating the versatility of Terumo BCT’s Finia automated fill and finish system in a range of cell and gene therapy (CGT) workflows. The platform was designed to streamline the cooling, aliquoting and packaging steps of cellular product manufacturing, where reproducibility is challenging and cost per failure remains highest.

Miami, Florida, August 13, 2024 – OrganaBio, the cell and gene therapy industry’s hub for tissue sourcing, cell isolation, cryopreservation and clinical sample processing, today announces two new partners that will utilize its current Good Manufacturing Practice (cGMP)-grade cryopreserved (cryo) leukopaks for clinical manufacturing of cell and cell-based therapies. Apheresis material was cryopreserved at OrganaBio’s FDA-registered GMP manufacturing facility, and the cGMP cryo leukopaks are now being shipped to three partners in the United States and abroad with ongoing active studies at pre-clinical and clinical stages.

Mulhouse, France, and Sunnyvale, Ca, US, July 08, 2024 - CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announce success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI) led by CellProthera, as well as plans to continue the relationship into Phase III.

Mataró, Barcelona, Spain, 11 June, 2024 - Minoryx Therapeutics (“Minoryx”), a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announce that results from a compassionate use study of leriglitazone for treatment of progressive cerebral adrenoleukodystrophy (cALD) in adult male patients, published1in the peer-reviewed journal Brain.

Lisboa, Portugal, June 07, 2024 – The MAGIC Consortium is proud to announce the participation of Instituto de Medicina Molecular João Lobo Antunes (iMM) in the MAGIC Project. This expansion is supported through the HORIZON-WIDERA-2023-ACCESS call that aims to widen participation and strengthen the European Research Area.

Miami, Florida, June 05, 2024 – OrganaBio, the cell and gene therapy industry’s hub for tissue sourcing, cell isolation, cryopreservation, contract manufacturing services and clinical sample processing, today announced the expansion of its flagship Cell Processing and Cryopreservation (CPC) Services hub in Irvine, California to support clinical trial services for a large-cap pharmaceutical company. The expansion comes a year after opening the Irvine lab and just months after the October launch of OrganaBio’s CPC Services division.

Kansas City, MO and Franklin, MA, Jun 3, 2024 – Likarda, Inc., leading biotech company specializing in the development of enabling technologies for the delivery of both cell therapies and large molecule biologics, and Cold Chain Technologies, LLC (CCT), a global provider of thermal packaging solutions for the transportation of temperature-sensitive products for the life sciences industry, are pleased to announce a new exclusive licensing agreement to improve the difficult logistics needed for cell therapy manufacturing.

St. Paul, MN, May 29, 2024 – ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene-modified cell therapies (CGT).

Lakewood, Colorado, 21 May 2024 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, announced the promotion of Mani Venkatesh to Vice President of Digital Transformation (DX), heading the company’s new Digital Transformation Office (DX Office) and joining the Executive Management Committee. Following over two decades in the healthcare industry, Venkatesh joined Terumo BCT in 2020 as Vice President of Global Software Engineering, where he played a critical role in driving efficiencies for customers and helping lead company growth.

Mulhouse, France, May 14, 2024, 11:00am CET – CellProthera, a regenerative cell therapy company developing breakthrough treatments for ischemic diseases, announced positive results from a Phase I/IIb study of its lead ProtheraCytes® in patients following a severe heart attack, positioning the stem cell therapy as a promising option to repair and regenerate heart tissue. The data was presented today by Faiez Zannad, MD, PhD, chairman of the study’s steering committee and emeritus professor of therapeutics at the Université of Lorraine.

Kansas City, USA, April 17, 2024 – Likarda, a leading biotech company specializing in the development of enabling technologies for the delivery of both cell therapies and large molecule biologics, today announces the appointment of Shelly Adams as Chief Commercial Officer. Shelly joins Likarda from Erbi Biosystems, part of Millipore Sigma, where she served as Vice President of Sales......

Mont-Saint-Guibert, Belgium, April 12, 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, as part of the global restructuring plan announced on 11 April 2024, provides information on (i) the Company's current debt position and the potential impact of the plan on this position .....

Mont-Saint-Guibert, Belgium, April 11, 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy announces that it has finalised a draft plan with the request referred to in Article XX 83/26 ELC with the Enterprise Court of Nivelles. Creditors will be notified to register their claims in RegSol. They will be able to consult this plan in order to then vote on the proposals made.

Ormond Beach, Florida and Germantown, Maryland, April 10, 2024 - Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and strategic partnership aimed at advancing Orgenesis’ therapeutic programs

Giessen, Hesse, Germany, April 9 2024 – Green Elephant Biotech GmbH, the world's first company to develop, manufacture and sell consumables for laboratories made from plant-based plastics, is expanding its product line of plant-based 96-well plates with two new additions for fluorescence- and luminescence-based assays. The new black and white microtiter plates....

Miami, Florida, April 3, 2024 – OrganaBio, the cell and gene therapy industry’s hub for tissue sourcing, cell isolation, cryopreservation, contract manufacturing services, and clinical sample processing, today announced the launch of HematoPAC™-HSC-CB-GMP, on-demand current good manufacturing practice (cGMP)-compliant CD34+ hematopoietic stem cells....

Mont-Saint-Guibert, Belgium, March 29, 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published....

Mont-Saint-Guibert, Belgium, 20 March 2024, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, presented the latest data on arsenic trioxide (ATO) for systemic sclerosis (SSc) at the 8th Systemic Sclerosis World Congress 2024. The data, obtained with the laboratory of Yannick Allanore, MD, Ph.D. from the Hospital Cochin, builds additional evidence....

Lakewood, Colorado, and Kyoto, Japan, March 19, 2024 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, and CiRA Foundation, a public interest organization for the transfer of induced pluripotent stem (iPS) cells to industry, today announced a partnership designed to propel the broad use of iPS cells for a range of new therapies. By leveraging CiRA Foundation’s leading iPS cell knowledge and Terumo BCT’s enabling technologies....

Mont-Saint-Guibert, Belgium, 12 March 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces the publication of an open-access article describing an optimized schedule for administration of oral arsenic trioxide (OATO) treatment for chronic graft-versus-host disease (cGvHD), based on an earlier post-hoc analysis of Phase 2 data. The schedule will play an important role in the protocol for BioSenic’s forthcoming pivotal Phase 3 clinical trial.

Lakewood, Colorado and Newark, N.J., February 29, 2024 – Today, Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company , and BioCentriq, a global cell therapy contract development and manufacturing organization (CDMO), will share the first data resulting from its chimeric antigen receptor (CAR)-T cell therapy manufacturing collaboration today at the 7th CAR TCR Summit Europe. The data will demonstrate, for the first time, the ability to rapidly produce CAR-T cells using protocols developed by Terumo BCT ....

Mont-Saint-Guibert, Belgium, 29 February 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information ....

Cardiff, UK, February 28, 2024 – TrakCel, the leading and proven provider of cellular orchestration systems to the global cell and gene therapy (CGT) industry, announces the coming expansion of its OCELLOS partner ecosystem, which will bring the total number of integrated partners to 20 by the end of 2024. The growth will mean developers using OCELLOS for cellular orchestration....

Mulhouse, France, February 27 2024 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, announces a collaboration with stem cell leaders at Shonan Kamakura General Hospital (SKGH), Japan, to manufacture autologous endothelial progenitor cells (EPCs) in forthcoming clinical trials. SKGH researchers led by world-renowned stem cell expert Takayuki Asahara, M.D., Ph.D., will deploy CellProthera’s clinically validated StemXpand(R) automated ....

Lakewood, Colorado, 19 February, 2024 - Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company , announced the publication of a peer-reviewed study [1] containing new consensus recommendations from an international panel of multidisciplinary experts for sickle cell disease (SCD) management during pregnancy. The Terumo BCT-sponsored study spells out....

Wednesday, 14th February 2024 - Children, young people, and adults across England suffering from sickle cell disease will soon benefit from better care closer to where they live, following the announcement of a £1.5m investment in 25 red blood cell exchange devices. Funding for the Spectra Optia(R) Apheresis System devices has been distributed to 22 NHS trusts*, with the devices set to be installed in hospitals for the treatment of patients by the end of March 2024.

Mont-Saint-Guibert, Belgium, 2 February 2024 – BioSenic (Euronext Brussels and Paris: BIOS),

Mont-Saint-Guibert, Belgium, January 31, 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it will attend and support the upcoming GvHGvL Meeting on 13-15 March, 2024 at University Hospital Regensburg, a biannual conference to lead scientific exchange around graft-versus-host disease (GvHD).

Berlin, Germany, January 31, 2024 – Green Elephant Biotech GmbH, the world's first company to develop, manufacture and sell consumables for laboratories made from plant-based plastics, today announces the commercial launch of the first-of-its-kind plant-based Green Elephant 96-Well Plate. For the first time, laboratory staff can conduct research, diagnoses and analysis more sustainably without compromising quality, all while meeting safety and purity standards. The plate is designed to replace single-use, fossil fuel-based plastic plates.

Mont-Saint-Guibert, Belgium, 30 January 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell repair therapy, today announces the granting of a key patent by the Canadian Intellectual Property Office to expand protection of the arsenic trioxide (ATO) platform. The patent, titled “Use of metal ions to potentiate the therapeutic effects of arsenic,” covers the use of ATO platform....

Mont-Saint-Guibert, Belgium, January 25 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will for the first time share post hoc data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024. The post hoc analysis of a Phase 3 study found that a single injection ....

Mont-Saint-Guibert, Belgium, January 23, 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company focused on serious autoimmune and inflammatory diseases and cell therapy, today announces the filing of a U.S. patent for JTA-004, a viscosupplement in late-stage clinical development, following new evidence of its efficacy in a recently defined subtype of osteoarthritis (OA).

Besançon, France, January 16, 2024 – CellQuest, a developer and manufacturer of automated chimeric antigen receptor (CAR)-T cell production platforms and solutions, today announces the launch of its Early Access Program (EAP) to introduce the CosyNest manufacturing platform to cell therapy developers. CosyNest, a closed manufacturing system, has been designed to dramatically increase the production of CAR-T cells per person, and per unit area.

Cardiff, UK, January 16, 2024 – TrakCel, the leading and proven provider of cellular orchestration systems to the global cell and gene therapy (CGT) industry, today launched TrakCel Consultancy Services to efficiently share its extensive process development experience with the broader community of CGT developers. The new consultancy services...

Miami, Florida, January 16, 2024 – OrganaBio, the hub for tissue sourcing, cell isolation, clinical sample processing, cryopreservation, and contract manufacturing services to support cell therapy and immunotherapy development globally, has been named a Translator of the Year finalist at the upcoming Advanced Therapies Awards for its work to support a chimeric antigen receptor natural killer T-cell (CAR-NKT) therapy as it progresses into clinical trials.........

Mont-Saint-Guibert, Belgium, January 15, 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announce the signature of a binding term sheet with Phebra PTY Ltd. related to the adaptation of the License Agreement and the MDA signed in May 2021.

Mont-Saint-Guibert, Belgium, January 10, 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announces the promotion of Dr Carole Nicco to Chief Operating Officer (COO) in addition to her position as Chief Scientific Officer (CSO).

Mont-Saint-Guibert, Belgium, January 8, 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the company addressing unmet medical needs in auto-immune diseases and orthopedics, today announces that it has signed a new subscription agreement for a maximum EUR 1.2 million convertible bonds ("CBs") facility, arranged by ABO Securities through its affiliated entity Global Tech Opportunities 15 ("GTO 15").